Search Medical Condition
Please enter condition
Please choose location from dropdown

Saddle Brook, New Jersey Clinical Trials

A listing of Saddle Brook, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (405) clinical trials

Study of Robot-assisted Arm Therapy for Acute Stroke Patients

HYPOTHESES - Motor function will be significantly greater for the patients in the robotic training group as measured by standard clinical evaluations. - Functional independence gains will be similar for both groups because the robotic therapy is not task-specific for activities of daily living (ADL). - Robotic training will reduce ...

Phase

0.28 miles

Learn More »

Robot Assisted Virtual Rehabilitation for the Hand Post Stroke (RAVR)

This study investigates the effects of high dosage task and impairment based training of the hemiparetic hand, using haptic robots integrated with complex gaming and virtual reality simulations on recovery and function of the hand, when the training is initiated within early period of heightened plasticity. The intervention uses two ...

Phase N/A

0.28 miles

Learn More »

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.

Phase

2.35 miles

Learn More »

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, non rhabdomyosarcomatous soft ...

Phase

2.58 miles

Learn More »

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) ...

Phase N/A

2.62 miles

Learn More »

Observational Registry of H.P. Acthar Gel for Multiple Sclerosis Relapse

H.P. Acthar Gel (repository corticotropin injection) contains a porcine analogue of adrenocorticotropic hormone (ACTH) for intramuscular or subcutaneous use. H.P. Acthar Gel (Acthar Gel) was initially approved by the FDA in 1952 and has multiple indications of use. This registry will evaluate the use of Acthar Gel for the treatment ...

Phase N/A

2.62 miles

Learn More »

Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris

This is an open-label, maximal use study evaluating the drug interaction potential of luliconazole cream 1% in subjects with tinea pedis and tinea cruris

Phase

2.62 miles

Learn More »

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...

Phase

2.62 miles

Learn More »

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Phase

2.62 miles

Learn More »

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine ...

Phase N/A

2.62 miles

Learn More »